.25 mg semaglutide Wegovy 0.25 such as those who are obese or have weight Obesema 0.25mg Injection - Semaglutide

Particularly beneficial for patients with insulin resistance or PCOS in weight management programs

The median follow-up time was 3.8 years

At InjectCo, compounded GLP-1 medications are sourced from a licensed 503B compounding pharmacy and are only incorporated into a program after clinical evaluation and approval

those prescribed semaglutide are more than 7 times more likely to receive a diagnosis of NAION than similar patients who do not take the drug

Robert Friedlander, Chair of the Department of Neurological Surgery, for providing me with the invaluable opportunity to work within the department and for his support in the development of this manuscript